Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Pituitary Neoplasms 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Pituitary ACTH Hypersecretion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Everolimus 5pembrolizumab 2cabozantinib 2Trastuzumab 2Nivolumab 2vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1spartalizumab 1romidepsin 1regorafenib 1pentetreotide 1guadecitabine 1fostamatinib 1exemestane 1entrectinib 1entinostat 1belzutifan 1avelumab 1alectinib 1Vinorelbine 1Sirolimus 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nephrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Rosiglitazone × Endocrine × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡